Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 5
1970 2
1971 2
1973 4
1974 3
1975 5
1976 2
1977 4
1978 6
1979 4
1980 5
1981 6
1982 1
1983 6
1984 3
1985 3
1986 2
1987 3
1988 6
1989 1
1990 2
1991 4
1992 1
1993 1
1994 2
1995 3
1996 1
1997 2
1998 4
1999 3
2000 8
2001 4
2002 3
2003 9
2004 4
2005 14
2006 15
2007 19
2008 27
2009 29
2010 33
2011 38
2012 36
2013 36
2014 37
2015 31
2016 40
2017 25
2018 35
2019 37
2020 37
2021 35
2022 26
2023 33
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

612 results

Results by year

Filters applied: . Clear all
Page 1
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, Guthrie V, McCoon P, Li W, Wu S, Zhang Q, Rebelatto MC, Kim JW. Oh DY, et al. Among authors: oh ks. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9. Lancet Gastroenterol Hepatol. 2022. PMID: 35278356 Clinical Trial.
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP. Tsien CI, et al. Among authors: oh ks. J Clin Oncol. 2023 Feb 20;41(6):1285-1295. doi: 10.1200/JCO.22.00164. Epub 2022 Oct 19. J Clin Oncol. 2023. PMID: 36260832 Free PMC article. Clinical Trial.
Parathyroid hemangioma.
Mejia O, Bahmad HF, Oh KS, Paramo JC, Poppiti R. Mejia O, et al. Among authors: oh ks. Autops Case Rep. 2021 May 25;11:e2021270. doi: 10.4322/acr.2021.270. eCollection 2021. Autops Case Rep. 2021. PMID: 34249786 Free PMC article. Review.
Overlooked KCNQ4 variants augment the risk of hearing loss.
Oh KS, Roh JW, Joo SY, Ryu K, Kim JA, Kim SJ, Jang SH, Koh YI, Kim DH, Kim HY, Choi M, Jung J, Namkung W, Nam JH, Choi JY, Gee HY. Oh KS, et al. Exp Mol Med. 2023 Apr;55(4):844-859. doi: 10.1038/s12276-023-00976-4. Epub 2023 Apr 3. Exp Mol Med. 2023. PMID: 37009795 Free PMC article.
Polysaccharide-based Nanoparticles for Gene Delivery.
Huh MS, Lee EJ, Koo H, Yhee JY, Oh KS, Son S, Lee S, Kim SH, Kwon IC, Kim K. Huh MS, et al. Among authors: oh ks. Top Curr Chem (Cham). 2017 Apr;375(2):31. doi: 10.1007/s41061-017-0114-y. Epub 2017 Mar 1. Top Curr Chem (Cham). 2017. PMID: 28251564 Review.
Double knockin mice show NF-κB trajectories in immune signaling and aging.
Rahman SMT, Aqdas M, Martin EW, Tomassoni Ardori F, Songkiatisak P, Oh KS, Uderhardt S, Yun S, Claybourne QC, McDevitt RA, Greco V, Germain RN, Tessarollo L, Sung MH. Rahman SMT, et al. Among authors: oh ks. Cell Rep. 2022 Nov 22;41(8):111682. doi: 10.1016/j.celrep.2022.111682. Cell Rep. 2022. PMID: 36417863 Free PMC article.
612 results